Journal article
Sushrusha Nayak, Phillip A. Doerfler, S. Porvasnik, D. Cloutier, R. Khanna, K. Valenzano, R. Herzog, B. Byrne
PLoS ONE, 2014
PLoS ONE, 2014
Semantic Scholar
DOI
PubMedCentral
PubMed
Cite
Cite
APA
Click to copy
Nayak, S., Doerfler, P. A., Porvasnik, S., Cloutier, D., Khanna, R., Valenzano, K., … Byrne, B. (2014). Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent. PLoS ONE.
Chicago/Turabian
Click to copy
Nayak, Sushrusha, Phillip A. Doerfler, S. Porvasnik, D. Cloutier, R. Khanna, K. Valenzano, R. Herzog, and B. Byrne. “Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and RhGAA Dose Dependent.” PLoS ONE (2014).
MLA
Click to copy
Nayak, Sushrusha, et al. “Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and RhGAA Dose Dependent.” PLoS ONE, 2014.
BibTeX Click to copy
@article{sushrusha2014a,
title = {Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent},
year = {2014},
journal = {PLoS ONE},
author = {Nayak, Sushrusha and Doerfler, Phillip A. and Porvasnik, S. and Cloutier, D. and Khanna, R. and Valenzano, K. and Herzog, R. and Byrne, B.}
}
Abstract
Enzyme replacement therapy (ERT) with recombinant human acid-α-glucosidase (rhGAA) is the only FDA approved therapy for Pompe disease. Without ERT, severely affected individuals (early onset) succumb to the disease within 2 years of life. A spectrum of disease severity and progression exists depending upon the type of mutation in the GAA gene (GAA), which in turn determines the amount of defective protein produced and its enzymatic activity. A large percent of the early onset patients are also cross reactive immunological material negative (CRIM-) and develop high titer immune responses to ERT with rhGAA. New insights from our studies in pre-clinical murine models reveal that the type of Gaa mutation has a profound effect on the immune responses mounted against ERT and the associated toxicities, including activation of clotting factors and disseminated intravascular coagulation (DIC). Additionally, the mouse strain affects outcomes, suggesting the influence of additional genetic components or modifiers. High doses of rhGAA (20 mg/kg) are currently required to achieve therapeutic benefit. Our studies indicate that lower enzyme doses reduce the antibody responses to rhGAA, reduce the incidence of immune toxicity and avoid ERT-associated anaphylaxis. Therefore, development of rhGAA with increased efficacy is warranted to limit immunotoxicities.